Short Interest in Bone Biologics Corp. (NASDAQ:BBLG) Declines By 72.2%

Bone Biologics Corp. (NASDAQ:BBLG) was the recipient of a large drop in short interest during the month of May. As of May 15th, there was short interest totaling 2,897 shares, a drop of 72.2% from the April 30th total of 10,427 shares. Currently, 0.2% of the shares of the company are sold short. Based on an average daily trading volume, of 9,614 shares, the days-to-cover ratio is currently 0.3 days.

Bone Biologics Stock Up 5.2%

BBLG opened at $1.31 on Friday. The firm has a market capitalization of $2.35 million, a P/E ratio of -0.57 and a beta of 0.89. The stock’s 50 day moving average price is $1.26 and its two-hundred day moving average price is $1.44. Bone Biologics has a 12-month low of $1.05 and a 12-month high of $6.75.

Bone Biologics (NASDAQ:BBLG) last released its earnings results on Thursday, May 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.43). As a group, analysts anticipate that Bone Biologics will post -1.52 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised Bone Biologics from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday, April 27th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

Institutional Trading of Bone Biologics

An institutional investor recently raised its position in Bone Biologics stock. DRW Securities LLC grew its position in Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 23,576 shares of the company’s stock after acquiring an additional 12,549 shares during the quarter. DRW Securities LLC owned 1.31% of Bone Biologics worth $34,000 as of its most recent SEC filing. 34.30% of the stock is currently owned by hedge funds and other institutional investors.

Bone Biologics Company Profile

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.